Request for Nominations of Candidates To Serve on the Clinical Laboratory Improvement Advisory Committee (CLIAC) and Request for Suggested Meeting Topics for CLIAC, 36543-36544 [2016-13438]
Download as PDF
Federal Register / Vol. 81, No. 109 / Tuesday, June 7, 2016 / Notices
placement of approximately 50,258
cubic yards of suitable oyster reef
substrate through the use of barges and
high-pressure water. Areas to be
restored would be marked with buoys or
clearly marked stakes. Following the
completion of the planting, oyster
density sampling would be conducted
and analyzed at a minimum of six
months, one year and two years after
clutching at each restoration site.
Ecological benefits associated with
the Project would be realized through an
array of ecological services in the form
of increased fishery and wildlife habitat;
increased biodiversity and trophic
dynamics; increased filtering capacity to
improve water quality and recycle
nutrients; increased structural stability
to reduce coastal erosion and to protect
near shore resources; protection of water
quality; and the protection of healthy,
diverse and sustainable living coastal
marine resources. Beyond the fact that
oysters and oyster reef communities
represent important food sources for
many species of commercially
important fish and invertebrates,
functioning oyster reefs are also
recognized as critical structural and
community components which stabilize
and sustain a broad array of ecological
relationships. Additional outcomes
include economic benefits through
harvesting, processing, and marketing
fishery products locally and regionally
by all who enjoy high-quality seafood.
Additional information on this
Project, including metrics of success,
response to science reviews and more is
available in an activity-specific
appendix to the FPL, which can be
found here: https://
www.restorethegulf.gov. (Please see the
table on page 24 of the FPL and click on
Apalachicola Bay Oyster Restoration,
Implementation.)
Justin R. Ehrenwerth,
Executive Director, Gulf Coast Ecosystem
Restoration Council.
[FR Doc. 2016–13356 Filed 6–6–16; 8:45 am]
BILLING CODE 6560–58–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
asabaliauskas on DSK3SPTVN1PROD with NOTICES
Centers for Disease Control and
Prevention
Request for Nominations of
Candidates To Serve on the Clinical
Laboratory Improvement Advisory
Committee (CLIAC) and Request for
Suggested Meeting Topics for CLIAC
The Centers for Disease Control and
Prevention (CDC) is soliciting
nominations for membership on CLIAC
VerDate Sep<11>2014
19:13 Jun 06, 2016
Jkt 238001
and soliciting suggestions for topics to
be considered for future Committee
deliberation. CLIAC provides scientific
and technical advice and guidance to
the Secretary, Department of Health and
Human Services (HHS); the Assistant
Secretary for Health, HHS; the Director,
Centers for Disease Control and
Prevention (CDC); the Commissioner,
Food and Drug Administration (FDA);
and the Administrator, Centers for
Medicare & Medicaid Services (CMS).
The advice and guidance pertain to
general issues related to improvement in
clinical laboratory quality and
laboratory medicine. In addition, the
Committee provides advice and
guidance on specific questions related
to possible revision of the CLIA
standards. Examples include providing
guidance on studies designed to
improve safety, effectiveness, efficiency,
timeliness, equity, and patientcenteredness of laboratory services;
revisions to the standards under which
clinical laboratories are regulated; the
impact of proposed revisions to the
standards on medical and laboratory
practice; and the modification of the
standards and provision of nonregulatory guidelines to accommodate
technological advances, such as new
test methods, the electronic
transmission of laboratory information,
and mechanisms to improve the
integration of public health and clinical
laboratory practices.
CLIAC consists of 20 members
including the Chair, and represents a
diverse membership across laboratory
specialties, professional roles
(laboratory management, technical
specialists, physicians, nurses) and
practice settings (academic, clinical,
public health), and includes a consumer
representative. In addition, the
Committee includes three ex officio
members (or designees), including the
Director, CDC; the Administrator, CMS;
and the Commissioner, FDA. A
nonvoting representative from the
Advanced Medical Technology
Association (AdvaMed) serves as the
industry liaison. The Designated Federal
Officer (DFO) or their designee and the
Executive Secretary are present at all
meetings to ensure meetings are within
applicable statutory, regulatory and
HHS General Administration manual
directives.
Request for Candidates: Nominations
are being sought for individuals who
have expertise and qualifications
necessary to contribute to
accomplishing CLIAC’s objectives.
Nominees will be selected by the HHS
Secretary or designee from authorities
knowledgeable across the fields of
microbiology (including bacteriology,
PO 00000
Frm 00028
Fmt 4703
Sfmt 4703
36543
mycobacteriology, mycology,
parasitology, and virology), immunology
(including histocompatibility),
chemistry, hematology, pathology
(including histopathology and cytology),
or genetic testing (including
cytogenetics); representatives from the
fields of medical technology, public
health, and clinical practice; and
consumer representatives. Members
may be invited to serve for terms of up
to four years.
The U.S. Department of Health and
Human Services policy stipulates that
Committee membership be balanced in
terms of professional training and
background, points of view represented,
and the committee’s function.
Consideration is given on the basis of
geographic, ethnic and gender
representation. Nominees must be U.S.
citizens, and cannot be full-time
employees of the U.S. Government.
Current participation on federal
workgroups or prior experience serving
on a federal advisory committee does
not disqualify a candidate; however,
HHS policy is to avoid excessive
individual service on advisory
committees and multiple committee
memberships. Committee members are
Special Government Employees,
requiring the filing of financial
disclosure reports at the beginning and
annually during their terms. CDC
reviews potential candidates for CLIAC
membership each year, and provides a
slate of nominees for consideration to
the Secretary of HHS for final selection.
HHS notifies selected candidates of
their appointment near the start of the
term in July, or as soon as the HHS
selection process is completed. Note
that the need for different expertise and
individuals to maintain the appropriate
demographic balance varies from year to
year and a candidate who is not selected
in one year may be reconsidered in a
subsequent year.
Candidates should submit the
following items to be considered for
nomination. The deadline for receipt of
materials for the 2017 term is August 1,
2016:
• Current curriculum vitae, including
complete contact information (name,
affiliation, mailing address, telephone
number, email address).
• Letter(s) of recommendation from
person(s) not employed by the U.S.
Department of Health and Human
Services.
Request for Suggested Meeting Topics:
Consideration of topics for meeting
agendas begins approximately four
months prior to each meeting. The
agendas are developed by CDC in
collaboration with CMS, FDA, and the
CLIAC Chair. Topics within the scope of
E:\FR\FM\07JNN1.SGM
07JNN1
36544
Federal Register / Vol. 81, No. 109 / Tuesday, June 7, 2016 / Notices
the Committee’s charge are selected and
questions for CLIAC deliberation are
developed to align with the agenda. The
agenda is published in the Federal
Register not less than 15 days before the
meeting date and is posted on the
CLIAC Web site (https://wwwn.cdc.gov/
cliac/default.aspx). Suggested meeting
topics are invited at any time for
consideration at future meetings.
Submission of Candidate Information
or Suggestions for Meeting Topics:
Candidate suggestions and potential
meeting topics may be submitted by:
• Email in care of the CLIAC
Secretariat at CLIAC@cdc.gov.
• U.S. Postal Service: Attention:
CLIAC Secretariat, 1600 Clifton Road
NE., Mailstop F–11, Atlanta, GA 30329.
Contact Person for Additional
Information: Nancy Anderson, Chief,
Laboratory Practice Standards Branch,
Division of Laboratory Systems, Center
for Surveillance, Epidemiology and
Laboratory Services, Office of Public
Health Scientific Services, Centers for
Disease Control and Prevention, 1600
Clifton Road NE., Mailstop F–11,
Atlanta, Georgia 30329–4018; telephone
(404) 498–2741; or via email at
NAnderson@cdc.gov. The Director,
Management Analysis and Services
Office, has been delegated the authority
to sign Federal Register notices
pertaining to announcements of
meetings and other committee
management activities for both the
Centers for Disease Control and
Prevention, and the Agency for Toxic
Substances and Disease Registry.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. 2016–13438 Filed 6–6–16; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention (CDC)
asabaliauskas on DSK3SPTVN1PROD with NOTICES
Office for State, Tribal, Local and
Territorial Support (OSTLTS)
In accordance with Presidential
Executive Order No. 13175, November
6, 2000, and the Presidential
Memorandum of November 5, 2009, and
September 23, 2004, Consultation and
Coordination with Indian Tribal
Governments, CDC/Agency for Toxic
Substances and Disease Registry
(ATSDR), announces the following
meeting and Tribal Consultation
Session:
VerDate Sep<11>2014
19:13 Jun 06, 2016
Jkt 238001
Name: Tribal Advisory Committee (TAC)
Meeting and 15th Biannual Tribal
Consultation Session.
Times and Dates:
8:00 a.m.–6:30 p.m., August 2, 2016, (TAC
Meeting)
8:00 a.m.–12:00 p.m., PDT, August 3, 2016,
PDT (TAC Meeting & 15th Biannual
Tribal Consultation Session)
Place: The TAC Meeting and Tribal
Consultation Session will be held at Rincon’s
Harrah, 77 Harrah’s Rincon Way, Valley
Center, California 92082, telephone (760)
362–8990.
Status: The meetings are being hosted by
CDC/ATSDR in-person only and are open to
the public. Attendees must pre-register for
the event by Wednesday, July 13, 2016, at the
following link: https://www.cdc.gov/tribal/
meetings.html.
Purpose: The purpose of these recurring
meetings is to advance CDC and ATSDR
support for and collaboration with American
Indian and Alaska Native (AI/AN) tribes, and
to improve the health of AI/AN tribes by
pursuing goals that include assisting in
eliminating the health disparities faced by
AI/AN tribes; ensuring that access to critical
health and human services and public health
services is maximized to advance or enhance
the social, physical, and economic status of
AI/ANs; and promoting health equity for all
Indian people and communities. To advance
these goals, CDC and ATSDR conducts
government-to-government consultations
with elected tribal officials or their
authorized representatives. Consultation is
an enhanced form of communication that
emphasizes trust, respect, and shared
responsibility. It is an open and free
exchange of information and opinion among
parties that leads to mutual understanding
and comprehension.
Matters for Discussion: The Summer 2016
TAC Meeting and Biannual Tribal
Consultation Session will provide
opportunities for tribal leaders to speak
openly about the public health issues
affecting their tribes. These meetings will
include, but are not limited to, discussions
about building tribal public health capacity,
intimate partner violence, and reducing
opioid dependence and overdose in Indian
country.
Tribes will also have an opportunity to
present testimony about tribal health issues.
All Tribal leaders are encouraged to submit
written testimony by 5:00 p.m., EDT,
Wednesday, July 13, 2016, to LCDR Jessica
Damon, Public Health Advisor for the Tribal
Support Unit, OSTLTS, via mail to 4770
Buford Highway NE., MS E–70, Atlanta,
Georgia 30341–3717 or email to
TribalSupport@cdc.gov.
Based on the number of tribal leaders
giving testimony and the time available, it
may be necessary to limit the time for each
presenter.
The agenda is subject to change as
priorities dictate. Information about the TAC,
CDC/ATSDR’s Tribal Consultation Policy,
and previous meetings can be found at https://
www.cdc.gov/tribal.
Contact person for more information:
LCDR Jessica Damon, Public Health Advisor,
CDC/OSTLTS, 4770 Buford Highway NE.,
PO 00000
Frm 00029
Fmt 4703
Sfmt 4703
MS E–70, Atlanta, Georgia 30341–3717;
email: TribalSupport@cdc.gov or telephone
(404) 498–0563.
The Director, Management Analysis and
Services Office, has been delegated the
authority to sign Federal Register notices
pertaining to announcements of meetings and
other committee management activities, for
both the Centers for Disease Control and
Prevention, and the Agency for Toxic
Substances and Disease Registry.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. 2016–13439 Filed 6–6–16; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[60Day–16–0770; Docket No. CDC–2016–
0047]
Proposed Data Collection Submitted
for Public Comment and
Recommendations
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice with comment period.
AGENCY:
The Centers for Disease
Control and Prevention (CDC), as part of
its continuing efforts to reduce public
burden and maximize the utility of
government information, invites the
general public and other Federal
agencies to take this opportunity to
comment on proposed and/or
continuing information collections, as
required by the Paperwork Reduction
Act of 1995. This notice invites
comment on the National HIV
Behavioral Surveillance (NHBS) system.
CDC is requesting a 3-year approval for
revision to the previously approved
project to continue collecting
standardized HIV-related behavioral
data from persons at risk for HIV
systematically selected from 25
Metropolitan Statistical Areas (MSAs)
throughout the United States.
DATES: Written comments must be
received on or before August 8, 2016.
ADDRESSES: You may submit comments,
identified by Docket No. CDC–2016–
0047 by any of the following methods:
• Federal eRulemaking Portal:
Regulations.gov. Follow the instructions
for submitting comments.
• Mail: Leroy A. Richardson,
Information Collection Review Office,
Centers for Disease Control and
Prevention, 1600 Clifton Road NE., MS–
D74, Atlanta, Georgia 30329.
SUMMARY:
E:\FR\FM\07JNN1.SGM
07JNN1
Agencies
[Federal Register Volume 81, Number 109 (Tuesday, June 7, 2016)]
[Notices]
[Pages 36543-36544]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-13438]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Request for Nominations of Candidates To Serve on the Clinical
Laboratory Improvement Advisory Committee (CLIAC) and Request for
Suggested Meeting Topics for CLIAC
The Centers for Disease Control and Prevention (CDC) is soliciting
nominations for membership on CLIAC and soliciting suggestions for
topics to be considered for future Committee deliberation. CLIAC
provides scientific and technical advice and guidance to the Secretary,
Department of Health and Human Services (HHS); the Assistant Secretary
for Health, HHS; the Director, Centers for Disease Control and
Prevention (CDC); the Commissioner, Food and Drug Administration (FDA);
and the Administrator, Centers for Medicare & Medicaid Services (CMS).
The advice and guidance pertain to general issues related to
improvement in clinical laboratory quality and laboratory medicine. In
addition, the Committee provides advice and guidance on specific
questions related to possible revision of the CLIA standards. Examples
include providing guidance on studies designed to improve safety,
effectiveness, efficiency, timeliness, equity, and patient-centeredness
of laboratory services; revisions to the standards under which clinical
laboratories are regulated; the impact of proposed revisions to the
standards on medical and laboratory practice; and the modification of
the standards and provision of non-regulatory guidelines to accommodate
technological advances, such as new test methods, the electronic
transmission of laboratory information, and mechanisms to improve the
integration of public health and clinical laboratory practices.
CLIAC consists of 20 members including the Chair, and represents a
diverse membership across laboratory specialties, professional roles
(laboratory management, technical specialists, physicians, nurses) and
practice settings (academic, clinical, public health), and includes a
consumer representative. In addition, the Committee includes three ex
officio members (or designees), including the Director, CDC; the
Administrator, CMS; and the Commissioner, FDA. A nonvoting
representative from the Advanced Medical Technology Association
(AdvaMed) serves as the industry liaison. The Designated Federal
Officer (DFO) or their designee and the Executive Secretary are present
at all meetings to ensure meetings are within applicable statutory,
regulatory and HHS General Administration manual directives.
Request for Candidates: Nominations are being sought for
individuals who have expertise and qualifications necessary to
contribute to accomplishing CLIAC's objectives. Nominees will be
selected by the HHS Secretary or designee from authorities
knowledgeable across the fields of microbiology (including
bacteriology, mycobacteriology, mycology, parasitology, and virology),
immunology (including histocompatibility), chemistry, hematology,
pathology (including histopathology and cytology), or genetic testing
(including cytogenetics); representatives from the fields of medical
technology, public health, and clinical practice; and consumer
representatives. Members may be invited to serve for terms of up to
four years.
The U.S. Department of Health and Human Services policy stipulates
that Committee membership be balanced in terms of professional training
and background, points of view represented, and the committee's
function. Consideration is given on the basis of geographic, ethnic and
gender representation. Nominees must be U.S. citizens, and cannot be
full-time employees of the U.S. Government. Current participation on
federal workgroups or prior experience serving on a federal advisory
committee does not disqualify a candidate; however, HHS policy is to
avoid excessive individual service on advisory committees and multiple
committee memberships. Committee members are Special Government
Employees, requiring the filing of financial disclosure reports at the
beginning and annually during their terms. CDC reviews potential
candidates for CLIAC membership each year, and provides a slate of
nominees for consideration to the Secretary of HHS for final selection.
HHS notifies selected candidates of their appointment near the start of
the term in July, or as soon as the HHS selection process is completed.
Note that the need for different expertise and individuals to maintain
the appropriate demographic balance varies from year to year and a
candidate who is not selected in one year may be reconsidered in a
subsequent year.
Candidates should submit the following items to be considered for
nomination. The deadline for receipt of materials for the 2017 term is
August 1, 2016:
Current curriculum vitae, including complete contact
information (name, affiliation, mailing address, telephone number,
email address).
Letter(s) of recommendation from person(s) not employed by
the U.S. Department of Health and Human Services.
Request for Suggested Meeting Topics: Consideration of topics for
meeting agendas begins approximately four months prior to each meeting.
The agendas are developed by CDC in collaboration with CMS, FDA, and
the CLIAC Chair. Topics within the scope of
[[Page 36544]]
the Committee's charge are selected and questions for CLIAC
deliberation are developed to align with the agenda. The agenda is
published in the Federal Register not less than 15 days before the
meeting date and is posted on the CLIAC Web site (https://wwwn.cdc.gov/cliac/default.aspx). Suggested meeting topics are invited at any time
for consideration at future meetings.
Submission of Candidate Information or Suggestions for Meeting
Topics: Candidate suggestions and potential meeting topics may be
submitted by:
Email in care of the CLIAC Secretariat at CLIAC@cdc.gov.
U.S. Postal Service: Attention: CLIAC Secretariat, 1600
Clifton Road NE., Mailstop F-11, Atlanta, GA 30329.
Contact Person for Additional Information: Nancy Anderson, Chief,
Laboratory Practice Standards Branch, Division of Laboratory Systems,
Center for Surveillance, Epidemiology and Laboratory Services, Office
of Public Health Scientific Services, Centers for Disease Control and
Prevention, 1600 Clifton Road NE., Mailstop F-11, Atlanta, Georgia
30329-4018; telephone (404) 498-2741; or via email at
NAnderson@cdc.gov. The Director, Management Analysis and Services
Office, has been delegated the authority to sign Federal Register
notices pertaining to announcements of meetings and other committee
management activities for both the Centers for Disease Control and
Prevention, and the Agency for Toxic Substances and Disease Registry.
Elaine L. Baker,
Director, Management Analysis and Services Office, Centers for Disease
Control and Prevention.
[FR Doc. 2016-13438 Filed 6-6-16; 8:45 am]
BILLING CODE 4163-18-P